Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:18 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors
NCT03627403 · University of Utah · PHASE2 · terminated · last registry update 2026-10-26 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “PI and Sponsor decision. Accrual was low and there was sufficient data to detect a response.” | – | Registry record, University of Utah |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against XPO1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-10-09Results posted on the registry: Karyopharm Therapeutics Inc, Selinexor 100 mg + Docetaxel (NCT04256707)
- 2026-09-15Results posted on the registry: Academic and Community Cancer Research United, Carfilzomib + Daratumumab (NCT04756401)
- 2026-08-10Results posted on the registry: Antengene Corporation, SVd (Selinexor+Bortezomib+dexamethasone) + Vd (Bortezomib+dexamethasone) (NCT04939142)
- 2026-06-03Phase 3 first posted: Innovent Biologics (Suzhou) Co. Ltd., Pomalidomide Capsules + Bortezomib for Injection (NCT07623798)
- 2026-05-12Phase 3 first posted: Shandong New Time Pharmaceutical Co., LTD, F182112 single-agent + Pomalidomide + Bortezomib + Dexamethasone (PVd) or Selinexor + Bortezomib + Dexamethasone (SVd) (NCT07579234)
- 2026-05-06Phase 3 first posted: Chia Tai Tianqing Pharmaceutical Group Co., Ltd., TQB2934 injection + Pomalidomide Capsule (NCT07569757)
- 2026-03-06Results posted on the registry: University of Colorado, Denver, Selinexor + Pomalidomide (NCT04925193)
- 2026-01-29Results posted on the registry: Mamta Parikh, Pembrolizumab + Selinexor (NCT04856189)
- 2026-01-29Also stopped (terminated): Mamta Parikh, Pembrolizumab + Selinexor (NCT04856189)
- 2026-01-27Phase 3 first posted: Beijing Friendship Hospital, golidocitinib + Selinexor (combination therapy) (NCT07369739)
- 2026-01-05Also stopped (terminated): Antengene Corporation, ICE [ifosfamide+carboplatin+etoposide] + GEMOX [gemcitabine+oxaliplatin] (NCT04425070)
- 2026-01-05Also stopped (terminated): Universitätsklinikum Hamburg-Eppendorf, Allogeneic Stem Cells + carfilzomib/lenalidomide/dexamethasone (KRD) (NCT05675319)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision